V. Pettirossi

发表

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Paola Fazi, Marco Vignetti, Natalia Meani, 2005, The New England journal of medicine.

A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF

S. Pileri, N. Bolli, B. Falini, 2009, Leukemia.

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

B. Falini, C. Vetro, L. Brunetti, 2015, Blood.

Differential expression of CD44 isoforms during liver regeneration in rats.

M. V. Magni, C. Riccardi, G. Servillo, 2001, Journal of hepatology.

Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients.

B. Falini, S. Ascani, G. Schiavoni, 2021, Blood cancer discovery.

Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma.

B. Falini, S. Ascani, G. Schiavoni, 2021, Cancer discovery.

Signaling Pathway to the Phosphatidylinositol 3-Kinase / Akt Protein Inhibits Apoptosis by Coupling Ret ) Adaptor ShcC ( Rai The Neuron-Specific

P. Pelicci, M. Santoro, R. Melillo, 2002 .

HOPS: a novel cAMP-dependent shuttling protein involved in protein synthesis regulation

G. Servillo, M. Viola-Magni, V. Pettirossi, 2005, Journal of Cell Science.

A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia

N. Bolli, B. Falini, G. Meloni, 2008, Leukemia.

Selective Silencing of the NPM1 Mutant Protein and Apoptosis Induction upon ATRA In Vitro Treatment of AML Cells Carrying NPM1 Mutations.

B. Falini, M. Martelli, I. Nicoletti, 2007 .

Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML

N. Bolli, B. Falini, M. Martelli, 2008, Leukemia.

Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to SUMO-1 in murine thymocytes

T. Kang, C. Riccardi, D. Delfino, 2011, Cell Death and Differentiation.

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Alexander V Penson, L. Pasqualucci, R. Rabadán, 2018, Blood.

The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor

B. Falini, H. Drexler, G. Schiavoni, 2023, Leukemia.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?

B. Falini, M. Martelli, Federica Cecchetti, 2011, Blood reviews.

BRAF mutations in hairy-cell leukemia.

S. Pileri, L. Pasqualucci, L. Farinelli, 2011, The New England journal of medicine.

Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI.

S. Pileri, N. Bolli, B. Falini, 2005, Blood.

Shc signaling in differentiating neural progenitor cells

P. Pelicci, M. Peschanski, L. Bonfanti, 2001, Nature Neuroscience.

The Neuron-Specific Rai (ShcC) Adaptor Protein Inhibits Apoptosis by Coupling Ret to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway

P. Pelicci, M. Santoro, R. Melillo, 2002, Molecular and Cellular Biology.

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

B. Falini, L. Klein-Hitpass, R. Mannucci, 2015, Blood.

The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues

S. Pileri, B. Falini, D. Conte, 2009, Haematologica.

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

E. Campo, S. Pileri, A. Navarro, 2009, The American journal of pathology.

Evidence for CD34+ Hematopoietic Progenitor Cell Involvement in Acute Myeloid Leukemia with NPM1 Gene Mutation: Implications for the Cell of Origin

B. Falini, M. Martelli, G. Specchia, 2008 .

Genomics of Hairy Cell Leukemia

Brunangelo Falini, Enrico Tiacci, B. Falini, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.

B. Falini, M. Martelli, L. del Vecchio, 2010, Blood.

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

B. Falini, S. Ascani, G. Schiavoni, 2021, Leukemia.

Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia

B. Falini, S. Ascani, G. Inghirami, 2013, Haematologica.

Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas

S. Pileri, H. Stein, N. Bolli, 2007, Leukemia.

Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.

B. Falini, S. Ascani, G. Inghirami, 2012 .

Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia.

B. Falini, H. Drexler, E. Tiacci, 2012, Blood.